Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04727632 · ClinicalTrials.gov registry record · Early Phase 1

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

A Early Phase 1 study, sponsored by University of Utah.

Terminated
Registry status
Early Phase 1
Development phase
2
Enrollment target

NCT04727632 is a Early Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04727632, a Early Phase 1 study, was terminated before completion, sponsored by University of Utah.

TERMINATED
Registry status
Early Phase 1
Development phase
2 participants
Enrollment target

Study Summary

This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide therapeutic decision making for functional precision oncology trials. The unique ability of FES-PET/CT to show absence of functional estrogen receptors throughout the entire body may improve confidence among research oncologists that an ER+ metastatic breast cancer patient is truly refractory to hormonal therapies which is a critical determination in the study design of the FORESEE trial.

Interventions

  • DRUG [18F]Fluoroestradiol (FES) PET/CT

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2021-03-31
Est. Completion 2024-07-30
Phase Early Phase 1

Sponsor

University of Utah

818 total trials

What the Registry Record Tells You About NCT04727632

The ClinicalTrials.gov registry entry for NCT04727632 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which [18F]Fluoroestradiol (FES) PET/CT is the first listed.

NCT04727632 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04727632 about?

NCT04727632 is a clinical study titled "[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial". This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide therapeutic decision making for functional precision oncology trials. The unique ability of FES-PET/CT to show absen...

What is the current status of trial NCT04727632?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2021-03-31. Estimated completion is 2024-07-30.

What interventions are being tested in trial NCT04727632?

The interventions under investigation include: [18F]Fluoroestradiol (FES) PET/CT (DRUG).

Who is sponsoring clinical trial NCT04727632?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.